Clinical trials: Difficile
Diarrhea, Clostridium Difficile
Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.
The objective of this study is to determine the efficacy of probiotics containing 25Bn (billion) CFU (colony-forming unit) of Lactobacillus rhamnosus, Sacchromyces boulardii and Bifidobacterium breve in the prevention of…
- Trial name
- NCT03647995
- Testing
- Probiolife by Green Made (Pharma M)
- Where
- Lebanon
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Yara El Helou
Clostridium Difficile Infection
Fidaxomicin to Prevent Clostridium Difficile Colonization
The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
- Trial name
- NCT01552668
- Testing
- Fidaxomicin
- Where
- United States
- Sponsor
- Washington University School of Medicine
Clostridium Difficile Infection, Clostridium Difficile Diarrhea
Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity
This Phase I, randomized, placebo-controlled, double-blinded, dose ranging study to assess the safety, tolerability, and immunogenicity of 2 dose levels of C. difficile vaccine.
- Trial name
- NCT00772954
- Testing
- Vaccine diluent buffer, Clostridium difficile toxoid vaccine (50 μg), Clostridium difficile toxoid vaccine (100 μg)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Clostridium Difficile
Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics
Purpose: To study the changes in the microbiome and stool composition in patients with Clostridium Difficile Infection (CDI) who undergo Fecal Microbiota Transplantation (FMT), along with changes in their clinical characteristics.
- Trial name
- FMT (NCT03117582)
- Testing
- Stool specimen
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of North Carolina, Chapel Hill
Clostridium Difficile
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
Phase 2, randomized, observer-blind, placebo-controlled, multi-centric study including 4 parallel study groups. 500 Subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be randomized in a (3:3:3:1)…
- Trial name
- NCT02316470
- Testing
- VLA84
- Where
- 10 sites in United States, Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Clostridium Difficile Diarrhea
Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients
The purpose of this study is to test if metronidazole prophylaxis is effective in decreasing the incidence of hospital induced Clostridium Difficile diarrhea among patients at high risk for this infection.
- Trial name
- NCT02200328
- Testing
- Metronidazole
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Alison Schneider
Clostridium Difficile Infection Recurrence
A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
This is a randomized, placebo-controlled, double-blind, multi-site study in which up to approximately 36 subjects with a recent C.
- Trial name
- NCT04891965
- Testing
- ART24
- Where
- 15 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Adiso Therapeutics
Clostridium Difficile, Colitis
The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers
The investigators hypothesize that development of symptoms characteristic of Clostridium difficile infection will be 2-3 times higher in asymptomatic carriers, compared to that of non carriers and expect to find risk factors for…
- Trial name
- NCT02063282
- Where
- Israel
- Volunteers
- 394 people
- Sponsor
- Amos Yinnon
Clostridium Difficile Infection
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the treatment of C. difficile infection. We hypothesize that alanyl-glutamine when given with standard antibiotic treatment for C.
- Trial name
- NCT02053350
- Testing
- Alanyl-glutamine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Virginia
Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI)
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
The purpose of this study is to investigate the plasma pharmacokinetics (PK) of fidaxomicin (FDX) and primary metabolite OP-1118 in Subjects with Inflammatory Bowel Disease (IBD) and C. difficile Infection (CDI).
- Trial name
- PROFILE (NCT02437591)
- Testing
- fidaxomicin
- Where
- 12 sites in Austria, France and 5 more
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma Europe Ltd.
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients.
- Trial name
- NCT05852587
- Testing
- Xylitol
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Brigham and Women's Hospital
Dysbiosis, Clostridium Difficile
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly.
- Conditions
- Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
- Trial name
- NCT05622721
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pennsylvania
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%).
- Trial name
- FILTRATE (NCT04960306)
- Testing
- Fecal filtrate transplantation, Conventional fecal microbiota transplantation
- Where
- Hungary
- Volunteers
- 238 people
- Sponsor
- University of Pecs
Clostridioides Difficile Infection
Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C.
- Trial name
- PREVENT (NCT06884748)
- Testing
- Ursodiol 500 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile Infection
Fecal Microbiota Transplant for Primary CDI
Clostridium difficile infection (CDI) is one of the most urgent health threats in the U.S. associated with antibiotic use. After an initial episode, disease recurrence is high and relapses can occur in 20-30% of people treated…
- Trial name
- NCT03795233
- Testing
- Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Medical Center
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical…
- Trial name
- NCT04317963
- Testing
- Bezlotoxumab, Standard CDI treatment
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Illinois at Chicago